Researchers at the School of Medicine have shown that levels of tau protein can be reduced – and some of the neurological damage caused by tau even reversed – by a synthetic molecule that targets genetic instructions. The findings are important for Alzheimer’s and other neurological diseases.
The School of Medicine has received a $4.3 million award from the Alzheimer’s Association to expand a major international clinical trial evaluating whether drugs can prevent Alzheimer’s disease in patients genetically predisposed to develop the devastating disease at a young age.
Using a new imaging agent that binds to tau protein and makes it visible in positron emission tomography (PET) scans, scientists at Washington University School of Medicine in St. Louis have shown that measures of tau are better markers of the cognitive decline characteristic of Alzheimer’s than measures of amyloid beta seen in PET scans.
The greatest risk factor for Alzheimer’s disease is advancing age. Researchers at Washington University School of Medicine in St. Louis have identified some of the key changes in the aging brain that lead to the increased risk. The changes center on amyloid beta 42, a main ingredient of Alzheimer’s brain plaques.
Randall J. Bateman, MD, the Charles F. and Joanne Knight Distinguished Professor of Neurology at the School of Medicine, has received a MetLife Foundation Award for Medical Research. Bateman, a leader in Alzheimer’s disease research, is the university’s fifth researcher to receive the prize.
Studying brain scans and cerebrospinal fluid of healthy adults, scientists have shown that changes in key markers of Alzheimer’s disease during midlife may help identify those who will develop dementia years later, according to new research.
Researchers have uncovered a unique connection between diabetes and Alzheimer’s disease, providing further evidence that a disease that robs people of their memories may be affected by elevated blood sugar, according to scientists at Washington University School of Medicine in St. Louis.
U.S. Sen. Roy Blunt, R-Mo., visited the Medical Campus this week to meet with physicians who treat patients with Alzheimer’s disease, and patients and caregivers who live with the debilitating disease every day. Blunt, pictured with physician-scientist Randall J. Bateman, chairs a subcommittee that oversees funding for medical research.
Depression and behavioral changes may occur before memory declines in people who will go on to develop Alzheimer’s disease, according to new research at the School of Medicine led by senior author Catherine M. Roe, PhD.
A protein that stimulates the brain to awaken from sleep may be a target for preventing Alzheimer’s disease, a study by School of Medicine researchers suggests. David M. Holtzman, MD, head of the Department of Neurology, is the study’s senior author.